Ventyx Biosciences, Inc.
VTYXDelisted Mar 4, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851194
Ventyx Biosciences, Inc. was delisted on Mar 4, 2026; its insiders filed their last Form 4 on Mar 4, 2026; 139 institutions reported holding it in 13F filings for Q4 2025, worth $471.6M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Ventyx Biosciences, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +41 vs. Q2 2022
- Shares held
- 39.3M
- +4.66M (+13.5%) vs. Q2 2022
- Total value
- $1.37B
- +$947.3M (+223.7%) vs. Q2 2022
- New holders
- 44
- 28 more added
- Sold out
- 3
- 21 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VTYX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 1 | $21.0K |
| Q4 2025 | 139 | $471.6M |
| Q3 2025 | 110 | $136.4M |
| Q2 2025 | 114 | $95.1M |
| Q1 2025 | 116 | $51.1M |
| Q4 2024 | 124 | $119.2M |
| Q3 2024 | 118 | $114.4M |
| Q2 2024 | 117 | $132.3M |
| Q1 2024 | 126 | $323.8M |
| Q4 2023 | 121 | $106.8M |
| Q3 2023 | 138 | $1.90B |
| Q2 2023 | 150 | $1.73B |
| Q1 2023 | 146 | $1.67B |
| Q4 2022 | 125 | $1.40B |
| Q3 2022 | 104 | $1.37B |
| Q2 2022 | 63 | $423.5M |
| Q1 2022 | 55 | $448.4M |
| Q4 2021 | 46 | $619.3M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Ventyx Biosciences, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 1,895,812 | $65.4M | 0.01% | +319,870+20.3% | Added |
| Citadel Advisors LLC | 3,471,164 | $121.2M | 0.15% | −420,164−10.8% | Reduced |
| Third Point LLCSuperinvestorThird Point | 4,312,834 | $150.6M | 2.72% | 00.0% | Unchanged |
| venBio Partners LLC | 5,011,536 | $175.0M | 40.48% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −206,400−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,052−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −36−100.0% | Sold out |